Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
Anabolic Effects : Increases nitrogen retention , protein synthesis , and cellular proliferation , making it a potent driver of hypertrophy and lean tissue gain
The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper compounded versions of the wildly popular medications
Los defectos de la enzima se traducen como un rasgo autosmico recesivo, con la enzima deficiente la 21-hidroxilasa en ms del 90% de los casos